Citations (90)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Véronique Ledroit, Cécile Debitus, Frédéric Ausseil, Roselyne Raux, Jean-Louis Menou & Bridget Hill. (2004) Heteronemin as a Protein Farnesyl Transferase Inhibitor. Pharmaceutical Biology 42:6, pages 454-456.
Read now
Read now
Herbert B Newton. (2003) Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways. Expert Review of Anticancer Therapy 3:5, pages 595-614.
Read now
Read now
Grace K. Dy & Alex A. Adjei. (2002) Farnesyltransferase Inhibitors in Breast Cancer Therapy. Cancer Investigation 20:sup2, pages 30-37.
Read now
Read now
Neena Rane & George C Prendergast. (2001) Farnesyltransferase inhibitors: mechanism and applications. Expert Opinion on Investigational Drugs 10:12, pages 2105-2116.
Read now
Read now
Articles from other publishers (86)
Ramona Hartinger, Eva-Maria Lederer, Elisa Schena, Giovanna Lattanzi & Karima Djabali. (2023) Impact of Combined Baricitinib and FTI Treatment on Adipogenesis in Hutchinson–Gilford Progeria Syndrome and Other Lipodystrophic Laminopathies. Cells 12:10, pages 1350.
Crossref
Crossref
Bruce D. Gelb, Marielle E. Yohe, Cordula Wolf & Gregor Andelfinger. (2022)
New prospectives on treatment opportunities in
RASopathies
. American Journal of Medical Genetics Part C: Seminars in Medical Genetics 190:4, pages 541-560.
Crossref
Crossref
Lydia Lam, Tien Tien, Mark Wildung, Laura White, Rance K. Sellon, Janean L. Fidel & Eric A. Shelden. (2022) Comparative whole transcriptome analysis of gene expression in three canine soft tissue sarcoma types. PLOS ONE 17:9, pages e0273705.
Crossref
Crossref
Patience Odeniyide, Marielle E. Yohe, Kai Pollard, Angelina V. Vaseva, Ana Calizo, Lindy Zhang, Fausto J. Rodriguez, John M. Gross, Amy N. Allen, Xiaolin Wan, Romel Somwar, Karisa C. Schreck, Linda Kessler, Jiawan Wang & Christine A. Pratilas. (2022) Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma. Oncogene 41:21, pages 2973-2983.
Crossref
Crossref
Michelle Yee Mun Teo, Jung Yin Fong, Wan Ming Lim & Lionel Lian Aun In. (2022)
Current Advances and Trends in
KRAS
Targeted Therapies for Colorectal Cancer
. Molecular Cancer Research 20:1, pages 30-44.
Crossref
Crossref
Lucia Sophie Kilian, Jakob Voran, Derk Frank & Ashraf Yusuf Rangrez. (2021) RhoA: a dubious molecule in cardiac pathophysiology. Journal of Biomedical Science 28:1.
Crossref
Crossref
J. Matthew Rhett, Imran Khan & John P. O’Bryan. 2020.
69
146
.
Rocío López-Posadas, Markus F. Neurath & Imke Atreya. (2016) Molecular pathways driving disease-specific alterations of intestinal epithelial cells. Cellular and Molecular Life Sciences 74:5, pages 803-826.
Crossref
Crossref
Alexander Golbraikh, Xiang Simon Wang, Hao Zhu & Alexander Tropsha. 2017. Handbook of Computational Chemistry. Handbook of Computational Chemistry
2303
2340
.
Peter C. Knipe, Sam Thompson & Andrew D. Hamilton. 2016. Macrocyclic and Supramolecular Chemistry. Macrocyclic and Supramolecular Chemistry
146
164
.
Alexander Golbraikh, Xiang S. Wang, Hao Zhu & Alexander Tropsha. 2016. Handbook of Computational Chemistry. Handbook of Computational Chemistry
1
48
.
Alexander Golbraikh, Xiang Simon Wang, Hao Zhu & Alexander Tropsha. 2016. Handbook of Computational Chemistry. Handbook of Computational Chemistry
1
38
.
Uyen B. Chu, Tyler Duellman, Sara J. Weaver, Yunting Tao & Jay Yang. (2015) Endothelial protective genes induced by statin are mimicked by ERK5 activation as triggered by a drug combination of FTI-277 and GGTI-298. Biochimica et Biophysica Acta (BBA) - General Subjects 1850:7, pages 1415-1425.
Crossref
Crossref
Behzad Yeganeh, Emilia Wiechec, Sudharsana R. Ande, Pawan Sharma, Adel Rezaei Moghadam, Martin Post, Darren H. Freed, Mohammad Hashemi, Shahla Shojaei, Amir A. Zeki & Saeid Ghavami. (2014) Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. Pharmacology & Therapeutics 143:1, pages 87-110.
Crossref
Crossref
Moon Hee Yang, Gaelle Laurent, Alexandra S. Bause, Robert Spang, Natalie German, Marcia C. Haigis & Kevin M. Haigis. (2013) HDAC6 and SIRT2 Regulate the Acetylation State and Oncogenic Activity of Mutant K-RAS. Molecular Cancer Research 11:9, pages 1072-1077.
Crossref
Crossref
Gabriella Misso, Gaia Giuberti, Angela Lombardi, Anna Grimaldi, Filippo Ricciardiello, Antonio Giordano, Pierosandro Tagliaferri, Alberto Abbruzzese & Michele Caraglia. (2013) Pharmacological inhibition of HSP90 and ras activity as a new strategy in the treatment of HNSCC. Journal of Cellular Physiology 228:1, pages 130-141.
Crossref
Crossref
M. H. Yang, S. Nickerson, E. T. Kim, C. Liot, G. Laurent, R. Spang, M. R. Philips, Y. Shan, D. E. Shaw, D. Bar-Sagi, M. C. Haigis & K. M. Haigis. (2012) Regulation of RAS oncogenicity by acetylation. Proceedings of the National Academy of Sciences 109:27, pages 10843-10848.
Crossref
Crossref
Alexander Golbraikh, Xiang Simon Wang, Hao Zhu & Alexander Tropsha. 2012. Handbook of Computational Chemistry. Handbook of Computational Chemistry
1309
1342
.
Sara Barberan, Kara McNair, Khalil Iqbal, Nicola C. Smith, George C. Prendergast, Trevor W. Stone, Stuart R. Cobb & Brian J. Morris. (2011) Altered apoptotic responses in neurons lacking RhoB GTPase. European Journal of Neuroscience 34:11, pages 1737-1746.
Crossref
Crossref
Barry J. Grant, Suryani Lukman, Harrison J. Hocker, Jaqueline Sayyah, Joan Heller Brown, J. Andrew McCammon & Alemayehu A. Gorfe. (2011) Novel Allosteric Sites on Ras for Lead Generation. PLoS ONE 6:10, pages e25711.
Crossref
Crossref
Stéphanie Duez, Laëtitia Coudray, Elisabeth Mouray, Philippe Grellier & Joëlle Dubois. (2010) Towards the synthesis of bisubstrate inhibitors of protein farnesyltransferase: Synthesis and biological evaluation of new farnesylpyrophosphate analogues. Bioorganic & Medicinal Chemistry 18:2, pages 543-556.
Crossref
Crossref
Lisa Pleyer, Daniel Neureiter, Victoria Faber & Richard Greil. 2010. Chronic Myeloid Neoplasias and Clonal Overlap Syndromes. Chronic Myeloid Neoplasias and Clonal Overlap Syndromes
153
222
.
Jijun Hao, Marie A. Daleo & Charles C. Hong. 2010. Systems Biology for Signaling Networks. Systems Biology for Signaling Networks
505
529
.
Minzhou Huang, Lisa D. Laury-Kleintop & George C. Prendergast. 2010. The Rho GTPases in Cancer. The Rho GTPases in Cancer
135
153
.
Herbert B. Newton. 2010. Glioblastoma. Glioblastoma
1
42
.
Sébastien Lethu, Maryon Ginisty, Damien Bosc & Joëlle Dubois. (2009) Discovery of a New Class of Protein Farnesyltransferase Inhibitors in the Arylthiophene Series. Journal of Medicinal Chemistry 52:20, pages 6205-6208.
Crossref
Crossref
Yuri K. Peterson, Xiang S. Wang, Patrick J. Casey & Alexander Tropsha. (2009) Discovery of Geranylgeranyltransferase-I Inhibitors with Novel Scaffolds by the Means of Quantitative Structure−Activity Relationship Modeling, Virtual Screening, and Experimental Validation. Journal of Medicinal Chemistry 52:14, pages 4210-4220.
Crossref
Crossref
Jennifer Kerhervé, Candice Botuha & Joëlle Dubois. (2009) New asymmetric synthesis of protein farnesyltransferase inhibitors via palladium-catalyzed cross-coupling reactions of 2-iodo-imidazoles. Organic & Biomolecular Chemistry 7:10, pages 2214.
Crossref
Crossref
David H. Gutmann. (2008) Using Neurofibromatosis-1 to Better Understand and Treat Pediatric Low-Grade Glioma. Journal of Child Neurology 23:10, pages 1186-1194.
Crossref
Crossref
Thorsten Braun & Pierre Fenaux. (2008) Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia. British Journal of Haematology 141:5, pages 576-586.
Crossref
Crossref
Joseph A. Sparano. 2008. Molecular Targeting in Oncology. Molecular Targeting in Oncology
55
73
.
Michele Caraglia, Monica Marra, Carlo Leonetti, Giuseppina Meo, Anna Maria D'Alessandro, Alfonso Baldi, Daniele Santini, Giuseppe Tonini, Raffaello Bertieri, Gabriella Zupi, Alfredo Budillon & Alberto Abbruzzese. (2007) R115777 (Zarnestra®)/Zoledronic acid (Zometa®) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. Journal of Cellular Physiology 211:2, pages 533-543.
Crossref
Crossref
F L Delarue, J Adnane, B Joshi, M A Blaskovich, D-A Wang, J Hawker, F Bizouarn, J Ohkanda, K Zhu, A D Hamilton, S Chellappan & S M Sebti. (2006) Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter. Oncogene 26:5, pages 633-640.
Crossref
Crossref
Jean Paul Klooster & Peter L. Hordijk. (2007) Targeting and localized signalling by small GTPases. Biology of the Cell 99:1, pages 1-12.
Crossref
Crossref
Renata Marcia de Figueiredo, Laëtitia Coudray & Joëlle Dubois. (2007) Synthesis and biological evaluation of potential bisubstrate inhibitors of protein farnesyltransferase. Design and synthesis of functionalized imidazoles. Organic & Biomolecular Chemistry 5:20, pages 3299.
Crossref
Crossref
Yuri K. Peterson, Patrick Kelly, Carolyn A. Weinbaum & Patrick J. Casey. (2006) A Novel Protein Geranylgeranyltransferase-I Inhibitor with High Potency, Selectivity, and Cellular Activity. Journal of Biological Chemistry 281:18, pages 12445-12450.
Crossref
Crossref
Sarah A. Holstein, Howard R. Knapp, Gerald H. Clamon, Daryl J. Murry & Raymond J. Hohl. (2005) Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemotherapy and Pharmacology 57:2, pages 155-164.
Crossref
Crossref
Junko Ohkanda, Corey L. Strickland, Michelle A. Blaskovich, Dora Carrico, Jeffrey W. Lockman, Andreas Vogt, Cynthia J. Bucher, Jiazhi Sun, Yimin Qian, David Knowles, Erin E. Pusateri, Saïd M. Sebti & Andrew D. Hamilton. (2006) Structure-based design of imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase. Organic & Biomolecular Chemistry 4:3, pages 482.
Crossref
Crossref
Iris T. Chan & D. Gary Gilliland. 2006. Principles of Molecular Medicine. Principles of Molecular Medicine
767
775
.
Laura L. Rokosz, Chia-Yu Huang, John C. Reader, Tara M. Stauffer, Daniel Chelsky, Nolan H. Sigal, Ashit K. Ganguly & John J. Baldwin. (2005) Surfing the piperazine core of tricyclic farnesyltransferase inhibitors. Bioorganic & Medicinal Chemistry Letters 15:24, pages 5537-5543.
Crossref
Crossref
Natalie M.G.M. Appels, Jos H. Beijnen & Jan H.M. Schellens. (2005) Development of Farnesyl Transferase Inhibitors: A Review. The Oncologist 10:8, pages 565-578.
Crossref
Crossref
In-Ah Kim, Sun-Sik Bae, Annemarie Fernandes, JunMin Wu, Ruth J. Muschel, W. Gillies McKenna, Morris J. Birnbaum & Eric J. Bernhard. (2005) Selective Inhibition of Ras, Phosphoinositide 3 Kinase, and Akt Isoforms Increases the Radiosensitivity of Human Carcinoma Cell Lines. Cancer Research 65:17, pages 7902-7910.
Crossref
Crossref
Nobunao Ikehara, Shuho Semba, Masanori Sakashita, Nobuo Aoyama, Masato Kasuga & Hiroshi Yokozaki. (2005)
BRAF
mutation associated with dysregulation of apoptosis in human colorectal neoplasms
. International Journal of Cancer 115:6, pages 943-950.
Crossref
Crossref
Debra Ferguson, Luis E. Rodriguez, Joann P. Palma, Marion Refici, Kenneth Jarvis, Jacqueline O'Connor, Gerard M. Sullivan, David Frost, Kennan Marsh, Joy Bauch, Haiying Zhang, Nan-Horng Lin, Saul Rosenberg, Hing L. Sham & Ingrid B.J.K. Joseph. (2005) Antitumor Activity of Orally Bioavailable Farnesyltransferase Inhibitor, ABT-100, Is Mediated by Antiproliferative, Proapoptotic, and Antiangiogenic Effects in Xenograft Models. Clinical Cancer Research 11:8, pages 3045-3054.
Crossref
Crossref
Saïd M. Sebti. (2005) Protein farnesylation: Implications for normal physiology, malignant transformation, and cancer therapy. Cancer Cell 7:4, pages 297-300.
Crossref
Crossref
Qun Li, Keith W. Woods, Weibo Wang, Nan-Horng Lin, Akiyo Claiborne, Wen-zhen Gu, Jerry Cohen, Vincent S. Stoll, Charles Hutchins, David Frost, Saul H. Rosenberg & Hing L. Sham. (2005) Design, synthesis, and activity of achiral analogs of 2-quinolones and indoles as non-thiol farnesyltransferase inhibitors. Bioorganic & Medicinal Chemistry Letters 15:8, pages 2033-2039.
Crossref
Crossref
Ming-Sing Si, Bruce A. Reitz & Dominic C. Borie. (2005) Inhibition of lymphocyte activation and function by the prenylation inhibitor L-778,123. Investigational New Drugs 23:1, pages 21-29.
Crossref
Crossref
Régis Millet, Juozas Domarkas, Raymond Houssin, Pauline Gilleron, Jean-François Goossens, Philippe Chavatte, Cédric Logé,, Nicole Pommery, Jean Pommery & Jean-Pierre Hénichart. (2004) Potent and Selective Farnesyl Transferase Inhibitors. Journal of Medicinal Chemistry 47:27, pages 6812-6820.
Crossref
Crossref
Kim, Troy S. Kleckley, Andrew J. Wiemer, Sarah A. Holstein, Raymond J. Hohl & David F. Wiemer. (2004) Synthesis and Activity of Fluorescent Isoprenoid Pyrophosphate Analogues. The Journal of Organic Chemistry 69:24, pages 8186-8193.
Crossref
Crossref
Qun Li, Akiyo Claiborne, Tongmei Li, Lisa Hasvold, Vincent S. Stoll, Steven Muchmore, Clarissa G. Jakob, Wendy Gu, Jerry Cohen, Charles Hutchins, David Frost, Saul H. Rosenberg & Hing L. Sham. (2004) Design, synthesis, and activity of 4-quinolone and pyridone compounds as nonthiol-containing farnesyltransferase inhibitors. Bioorganic & Medicinal Chemistry Letters 14:21, pages 5367-5370.
Crossref
Crossref
Michele Caraglia, Anna Maria D'Alessandro, Monica Marra, Gaia Giuberti, Giovanni Vitale, Caterina Viscomi, Annamaria Colao, Salvatore Del Prete, Pierosandro Tagliaferri, Pierfrancesco Tassone, Alfredo Budillon, Salvatore Venuta & Alberto Abbruzzese. (2004) The farnesyl transferase inhibitor R115777 (Zarnestra®) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa®) and Pamidronate. Oncogene 23:41, pages 6900-6913.
Crossref
Crossref
Julia Jitkova, Christina N. Carrigan, C. Dale Poulter & Sergey N. Krylov. (2004) Monitoring the three enzymatic activities involved in posttranslational modifications of Ras proteins. Analytica Chimica Acta 521:1, pages 1-7.
Crossref
Crossref
Matthew Wherlock, Alexandra Gampel, Clare Futter & Harry Mellor. (2004) Farnesyltransferase inhibitors disrupt EGF receptor traffic through modulation of the RhoB GTPase. Journal of Cell Science 117:15, pages 3221-3231.
Crossref
Crossref
H. Ishida. (2004) Botulinum Toxin Type A Targets RhoB to Inhibit Lysophosphatidic Acid-Stimulated Actin Reorganization and Acetylcholine Release in Nerve Growth Factor-Treated PC12 Cells. Journal of Pharmacology and Experimental Therapeutics 310:3, pages 881-889.
Crossref
Crossref
Xiao-hui Liu & Glenn D. Prestwich. (2004) Didehydrofarnesyl diphosphate: an intrinsically fluorescent inhibitor of protein farnesyltransferase. Bioorganic & Medicinal Chemistry Letters 14:9, pages 2137-2140.
Crossref
Crossref
Julien Mazieres, Anne Pradines & Gilles Favre. (2004) Perspectives on farnesyl transferase inhibitors in cancer therapy. Cancer Letters 206:2, pages 159-167.
Crossref
Crossref
Le Wang, Gary T. Wang, Xilu Wang, Yunsong Tong, Gerry Sullivan, David Park, Nicholas M. Leonard, Qun Li, Jerry Cohen, Wen-Zhen Gu, Haiying Zhang, Joy L. Bauch, Clarissa G. Jakob, Charles W. Hutchins, Vincent S. Stoll, Kennan Marsh, Saul H. Rosenberg, Hing L. Sham & Nan-Horng Lin. (2004)
Design, Synthesis, and Biological Activity of 4-[(4-Cyano-2-arylbenzyloxy)-(3-methyl-3
H
-imidazol-4-yl)methyl]benzonitriles as Potent and Selective Farnesyltransferase Inhibitors
. Journal of Medicinal Chemistry 47:3, pages 612-626.
Crossref
Crossref
Junko OhkandaFrederick S. BucknerJeffrey W. LockmanKohei YokoyamaDora CarricoRichard EastmanKate de Luca-FradleyWendy DaviesSimon L. CroftWesley C. Van VoorhisMichael H. GelbSaïd M. SebtiAndrew D. Hamilton. (2003)
Design and Synthesis of Peptidomimetic Protein Farnesyltransferase Inhibitors as Anti-
Trypanosoma brucei
Agents
. Journal of Medicinal Chemistry 47:2, pages 432-445.
Crossref
Crossref
Razelle KurzrockHagop M. KantarjianJorge E. CortesNeil SinghaniaDeborah A. ThomasEdward F. WilsonJohn J. WrightEmil J. FreireichMoshe TalpazSaïd M. Sebti. (2003) Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood 102:13, pages 4527-4534.
Crossref
Crossref
David M Vigushin, Greg Brooke, David Willows, R.Charles Coombes & Christopher J Moody. (2003) Pyrazino[1,2- a ]indole-1,4-diones, simple analogues of gliotoxin, as selective inhibitors of geranylgeranyltransferase I. Bioorganic & Medicinal Chemistry Letters 13:21, pages 3661-3663.
Crossref
Crossref
Sophie F. Doisneau-Sixou, Philippe Cestac, Jean-Charles Faye, Gilles Favre & Robert L. Sutherland. (2003) Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression. International Journal of Cancer 106:5, pages 789-798.
Crossref
Crossref
Zhongqiu Zhang, Yian Wang, Laura E Lantry, Elizabeth Kastens, Gongjie Liu, Andrew D Hamilton, Said M Sebti, Ronald A Lubet & Ming You. (2003) Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf. Oncogene 22:40, pages 6257-6265.
Crossref
Crossref
James L. Mulshine & Fred R. Hirsch. (2003) Lung cancer chemoprevention: moving from concept to a reality. Lung Cancer 41, pages 163-174.
Crossref
Crossref
Fred R. Hirsch, Giorgio V. Scagliotti, Corey J. Langer, Marileila Varella-Garcia & Wilbur A. Franklin. (2003) Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer 41, pages 29-42.
Crossref
Crossref
M. Eskandarpour, J. Hashemi, L. Kanter, U. Ringborg, A. Platz & J. Hansson. (2003) Frequency of UV-Inducible NRAS Mutations in Melanomas of Patients With Germline CDKN2A Mutations. JNCI Journal of the National Cancer Institute 95:11, pages 790-798.
Crossref
Crossref
Laszlo Kari, Andrey Loboda, Michael Nebozhyn, Alain H. Rook, Eric C. Vonderheid, Calen Nichols, Dezso Virok, Celia Chang, Wen-Hwai Horng, James Johnston, Maria Wysocka, Michael K. Showe & Louise C. Showe. (2003) Classification and Prediction of Survival in Patients with the Leukemic Phase of Cutaneous T Cell Lymphoma. The Journal of Experimental Medicine 197:11, pages 1477-1488.
Crossref
Crossref
R A Mesa, A Tefferi, L A Gray, T Reeder, G Schroeder & S H Kaufmann. (2003) In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia. Leukemia 17:5, pages 849-855.
Crossref
Crossref
Tianhong Li & Joseph A. Sparano. (2003) Inhibiting Ras Signaling in the Therapy of Breast Cancer. Clinical Breast Cancer 3:6, pages 405-416.
Crossref
Crossref
C. J. Newton, Y.-X. Xie, C. H. Burgoyne, I. Adams, S. L. Atkin, A. Abidia & P. T. McCollum. (2016) Fluvastatin Induces Apoptosis of Vascular Endothelial Cells: Blockade by Glucocorticoids. Cardiovascular Surgery 11:1, pages 52-60.
Crossref
Crossref
S C E Bolick, T H Landowski, D Boulware, M M Oshiro, J Ohkanda, A D Hamilton, S M Sebti & W S Dalton. (2003) The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. Leukemia 17:2, pages 451-457.
Crossref
Crossref
Irene M Ghobrial & Alex A Adjei. (2002) Inhibitors of the ras oncogene as therapeutic targets. Hematology/Oncology Clinics of North America 16:5, pages 1065-1088.
Crossref
Crossref
P Haluska, G.K Dy & A.A Adjei. (2002) Farnesyl transferase inhibitors as anticancer agents. European Journal of Cancer 38:13, pages 1685-1700.
Crossref
Crossref
Patrizia Russo, Davide Malacarne, Carla Falugi, Sonya Trombino & Patrick M. O'Connor. (2002) RPR-115135, a farnesyltransferase inhibitor, increases 5-FU- cytotoxicity in ten human colon cancer cell lines: Role of p53. International Journal of Cancer 100:3, pages 266-275.
Crossref
Crossref
Giovanni Selvaggi & Giorgio V. Scagliotti. (2002) Chemotherapy in Advanced non—small-Cell Lung Cancer: A Look Behind and Ahead. Clinical Lung Cancer 4:1, pages 26-34.
Crossref
Crossref
N C Crespo, F Delarue, J Ohkanda, D Carrico, A D Hamilton & S M Sebti. (2002) The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status. Cell Death & Differentiation 9:7, pages 702-709.
Crossref
Crossref
Kareem A. H. Chehade, Katarzyna Kiegiel, Richard J. Isaacs, Jennifer S. Pickett, Katherine E. Bowers, Carol A. Fierke, Douglas A. Andres & H. Peter Spielmann. (2002) Photoaffinity Analogues of Farnesyl Pyrophosphate Transferable by Protein Farnesyl Transferase. Journal of the American Chemical Society 124:28, pages 8206-8219.
Crossref
Crossref
Claire E. Walters, Gareth Pryce, Deborah J. R. Hankey, Said M. Sebti, Andrew D. Hamilton, David Baker, John Greenwood & Peter Adamson. (2002) Inhibition of Rho GTPases with Protein Prenyltransferase Inhibitors Prevents Leukocyte Recruitment to the Central Nervous System and Attenuates Clinical Signs of Disease in an Animal Model of Multiple Sclerosis. The Journal of Immunology 168:8, pages 4087-4094.
Crossref
Crossref
. (2002) Prospects for anti-ras drugs. British Journal of Haematology 116:3, pages 511-518.
Crossref
Crossref
Carlos L Arteaga, Fadlo Khuri, Geoffrey Krystal & Said Sebti. (2002) Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer. Seminars in Oncology 29:1, pages 15-26.
Crossref
Crossref
Walter M Stadler. (2002) Gemcitabine doublets in advanced urothelial cancer. Seminars in Oncology 29:1, pages 15-19.
Crossref
Crossref
Xue-Zhi Qin. (2001) Tandem mass spectrum of a farnesyl transferase inhibitor? gas-phase rearrangements involving imidazole. Journal of Mass Spectrometry 36:8, pages 911-917.
Crossref
Crossref
Eric B. Haura. (2017) Treatment of Advanced Non-Small-Cell Lung Cancer: A Review of Current Randomized Clinical Trials and an Examination of Emerging Therapies. Cancer Control 8:4, pages 326-336.
Crossref
Crossref
Reuben J. Shaw, J.Guillermo Paez, Marcello Curto, Ann Yaktine, Wendy Morse Pruitt, Ichiko Saotome, John P. O'Bryan, Vikas Gupta, Nancy Ratner, Channing J. Der, Tyler Jacks & Andrea I. McClatchey. (2001) The Nf2 Tumor Suppressor, Merlin, Functions in Rac-Dependent Signaling. Developmental Cell 1:1, pages 63-72.
Crossref
Crossref
Anthony W. Tolcher. (2001) Novel Compounds in the Therapy of Breast Cancer: Opportunities for Integration with Docetaxel. The Oncologist 6:S3, pages 40-44.
Crossref
Crossref
A. Kubo & F. J. Kaye. (2001) Searching for Selective Cyclin-Dependent Kinase Inhibitors to Target the Retinoblastoma/p16 Cancer Gene Pathway. JNCI Journal of the National Cancer Institute 93:6, pages 415-417.
Crossref
Crossref
Saïd M Sebti & Andrew D Hamilton. (2000) Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: Lessons from mechanism and bench-to-bedside translational studies. Oncogene 19:56, pages 6584-6593.
Crossref
Crossref